EA199700244A1 - Слитый белок, экспрессирующий вектор, рекомбинантный штамм, вакцинный препарат - Google Patents

Слитый белок, экспрессирующий вектор, рекомбинантный штамм, вакцинный препарат

Info

Publication number
EA199700244A1
EA199700244A1 EA199700244A EA199700244A EA199700244A1 EA 199700244 A1 EA199700244 A1 EA 199700244A1 EA 199700244 A EA199700244 A EA 199700244A EA 199700244 A EA199700244 A EA 199700244A EA 199700244 A1 EA199700244 A1 EA 199700244A1
Authority
EA
Eurasian Patent Office
Prior art keywords
coli
heterologous proteins
present
proteins
fusion polypeptides
Prior art date
Application number
EA199700244A
Other languages
English (en)
Other versions
EA000307B1 (ru
Inventor
Карлос Антонио Дуарте Кано
Херардо Энрике Гильен Ньето
Анабель Альварес Акоста
Эмилио Луис Карпио Муньос
Диогенес Кинтана Васкес
Кармен Элена Гомес Родригес
Рикардо де ла Каридад Сильва Родригес
Консуэло Насабаль Гальвес
Ангуло Мария де Хесус Леал
Алехандро Мигель Мартин Дунн
Original Assignee
Сентро Де Инженьериа Генетика И Биотекнологиа (Сигб)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=5459182&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA199700244(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сентро Де Инженьериа Генетика И Биотекнологиа (Сигб) filed Critical Сентро Де Инженьериа Генетика И Биотекнологиа (Сигб)
Publication of EA199700244A1 publication Critical patent/EA199700244A1/ru
Publication of EA000307B1 publication Critical patent/EA000307B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Настоящее изобретение относится к области биотехнологии и генной инженерии, а в частности к экспрессии гетерологичных белков в микроорганизмах путем их слияния с бактериальными пептидами с использованием техники рекомбинантных ДНК. Настоящее изобретение относится к способу эффективной экспрессии в E.coli гетерологичных белков как слитых полипептидов в целях получения нужных белков с высокой степенью чистоты в необходимых количествах, удобных для коммерческого использования, и в соответствующей форме для их включения в вакцинные препараты, предназначенные для введения человеку. Осуществление этого способа, в основном, предусматривает использование стабилизирующей последовательности, полученной из первых 47 аминокислот антигена P64K Neisseria meningitidis B:4:P1.15, в частности, для такого использования конструируют рекомбинантную плазмиду, содержащую указанную последовательность под контролем триптофанового промотора E.coli и терминатора транскрипции фага T4 и включающую сайты рестрикции, которые вводят в целях клонирования с сохранением рамки считывания, ДНК-фрагментов, кодирующих нужные полипептиды. Способ настоящего изобретения может быть применен в фармацевтической промышленности для разработки диагностических систем, вакцинных препаратов или для каких-либо других целей, где требуется получение высоких количеств гетерологичных белков в виде слитых полипептидов в E.coli.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199700244A 1996-01-17 1997-01-17 СЛИТЫЙ БЕЛОК, ВЕКТОР ЭКСПРЕССИИ СЛИТОГО БЕЛКА, РЕКОМБИНАНТНЫЙ ШТАММ БАКТЕРИЙ Escherichia coli И ВАКЦИННЫЙ ПРЕПАРАТ EA000307B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU1996010A CU22559A1 (es) 1996-01-17 1996-01-17 Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
PCT/CU1997/000001 WO1997026359A1 (es) 1996-01-17 1997-01-17 Sistema de expresion de antigenos heterologos como proteinas de fusion

Publications (2)

Publication Number Publication Date
EA199700244A1 true EA199700244A1 (ru) 1998-02-26
EA000307B1 EA000307B1 (ru) 1999-04-29

Family

ID=5459182

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199700244A EA000307B1 (ru) 1996-01-17 1997-01-17 СЛИТЫЙ БЕЛОК, ВЕКТОР ЭКСПРЕССИИ СЛИТОГО БЕЛКА, РЕКОМБИНАНТНЫЙ ШТАММ БАКТЕРИЙ Escherichia coli И ВАКЦИННЫЙ ПРЕПАРАТ

Country Status (22)

Country Link
US (2) US6146635A (ru)
EP (1) EP0816506B1 (ru)
JP (1) JP4071282B2 (ru)
KR (1) KR100500782B1 (ru)
CN (1) CN1107115C (ru)
AR (1) AR005651A1 (ru)
AT (1) ATE198491T1 (ru)
AU (1) AU722317B2 (ru)
BR (1) BR9704641B1 (ru)
CA (1) CA2214840A1 (ru)
CU (1) CU22559A1 (ru)
CZ (1) CZ291097A3 (ru)
DE (1) DE69703813T2 (ru)
DK (1) DK0816506T3 (ru)
EA (1) EA000307B1 (ru)
ES (1) ES2157060T3 (ru)
GR (1) GR3035690T3 (ru)
HU (1) HUP9800730A3 (ru)
IL (1) IL121614A (ru)
MX (1) MX9707071A (ru)
PT (1) PT816506E (ru)
WO (1) WO1997026359A1 (ru)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
BR9906927A (pt) 1998-01-14 2001-11-20 Chiron Spa Proteìnas de neisseria meningitidis
GB9808866D0 (en) * 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9810276D0 (en) 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
GB9818004D0 (en) * 1998-08-18 1998-10-14 Smithkline Beecham Biolog Novel compounds
EP1141313A2 (en) * 1998-12-31 2001-10-10 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
WO2000039303A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Modified hiv env polypeptides
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AUPQ347199A0 (en) * 1999-10-15 1999-11-11 Csl Limited Novel polypeptide fragments
CA2415923C (en) 2000-07-12 2011-10-25 Agensys, Inc. Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers
EP1313850B1 (en) 2000-08-28 2008-08-06 Agensys, Inc. Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
CA2443123A1 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
EP2292772A1 (en) * 2001-07-05 2011-03-09 Novartis Vaccines and Diagnostics, Inc. HIV vaccination with a DNA encoding a HIV polypeptide and a HIV polypeptide
AU2002320314A1 (en) * 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
CU23245A1 (es) 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
KR100447530B1 (ko) * 2001-08-14 2004-09-08 한국과학기술원 ＯｍｐＦ를 이용하여 목적 단백질을 대장균 세포외로분비생산하는 방법
WO2003020876A2 (en) 2001-08-31 2003-03-13 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
ES2532757T3 (es) 2001-09-06 2015-03-31 Agensys, Inc. Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
AU2002352976B2 (en) 2002-11-27 2007-11-08 Agensys, Inc. Nucleic acid corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
WO2004072263A2 (en) 2003-02-10 2004-08-26 Agensys, Inc. Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
PT1629088E (pt) 2003-05-30 2012-04-10 Agensys Inc Variantes de antigénio de células estaminais de próstata (psca) e subsequências das mesmas
US20050040037A1 (en) * 2003-08-20 2005-02-24 Walton Scott G. Electron beam enhanced large area deposition system
CU23237A1 (es) * 2003-12-03 2007-09-26 Ct Ingenieria Genetica Biotech PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS
CU23236A1 (es) * 2003-12-03 2007-09-26 Ct Ingenieria Genetica Biotech PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P
MXPA06013834A (es) 2004-05-28 2007-03-01 Agensys Inc Anticuerpos y moleculas relacionadas que enlazan a proteinas psca.
CN100518818C (zh) * 2004-11-15 2009-07-29 中国人民解放军军事医学科学院生物工程研究所 一种预防和/或治疗消化系统肿瘤的疫苗
RU2413735C2 (ru) 2005-03-31 2011-03-10 Эдженсис, Инк. Антитела и родственные молекулы, связывающиеся с белками 161p2f10b
CU23578A1 (es) 2005-09-16 2010-09-30 Ct Ingenieria Genetica Biotech Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
CU23630A1 (es) 2006-10-30 2011-02-24 Ct Ingenieria Genetica Biotech Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
US20110110974A1 (en) * 2007-10-29 2011-05-12 Erik Depla Methods and kits for inducing a ctl response using a prime boost regimen
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
EP2530159A1 (en) * 2011-06-03 2012-12-05 Sandoz Ag Transcription terminator sequences
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
CU20200075A7 (es) 2020-10-22 2022-05-11 Ct Ingenieria Genetica Biotecnologia Antígeno quimérico que comprende el dominio extracelular de pd-l1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0472658A4 (en) * 1989-05-19 1992-08-26 Biotechnology Res & Dev Fusion proteins having an in vivo post-translational modification site and methods of manufacture and purification
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales

Also Published As

Publication number Publication date
CN1107115C (zh) 2003-04-30
DK0816506T3 (da) 2001-05-21
KR100500782B1 (ko) 2005-11-25
JP4071282B2 (ja) 2008-04-02
CU22559A1 (es) 1999-05-03
EP0816506A1 (en) 1998-01-07
BR9704641B1 (pt) 2010-03-09
AU1539697A (en) 1997-08-11
ATE198491T1 (de) 2001-01-15
AU722317B2 (en) 2000-07-27
PT816506E (pt) 2001-06-29
AR005651A1 (es) 1999-07-14
EA000307B1 (ru) 1999-04-29
KR19980703043A (ko) 1998-09-05
IL121614A0 (en) 1998-02-08
DE69703813T2 (de) 2001-08-09
EP0816506B1 (en) 2001-01-03
HUP9800730A2 (hu) 1998-07-28
ES2157060T3 (es) 2001-08-01
US6921809B1 (en) 2005-07-26
CN1177982A (zh) 1998-04-01
CZ291097A3 (cs) 1998-11-11
HUP9800730A3 (en) 1999-07-28
CA2214840A1 (en) 1997-07-24
MX9707071A (es) 1997-11-29
US6146635A (en) 2000-11-14
BR9704641A (pt) 1998-06-09
DE69703813D1 (de) 2001-02-08
WO1997026359A1 (es) 1997-07-24
IL121614A (en) 2006-10-31
GR3035690T3 (en) 2001-07-31
JPH11503617A (ja) 1999-03-30

Similar Documents

Publication Publication Date Title
EA199700244A1 (ru) Слитый белок, экспрессирующий вектор, рекомбинантный штамм, вакцинный препарат
DE69229221T2 (de) Expression rekombinanter proteine in attenuierten bakterien
CN101321781A (zh) 一种核苷酸疫苗
KR20120099672A (ko) 발현 시스템
DE69430246D1 (de) Rekombinante tetc-fusionsprotein enthaltene impfstoffzusammensetzungen
NO902251L (no) Fremstilling av gonoreiske p1-proteiner og vaksiner.
Niitsu et al. Subunit heterogeneity in ferritin
ATE130370T1 (de) Verfahren zur expression von, als fusionsproteine produzierten, heterologen proteinen in e. coli, deren verwendungen, expressionsvektoren und rekombinante stämme.
KR880002894A (ko) 주혈흡충증왁진으로 사용되는 단백질과 dna 시퀀스
Jackson et al. Analysis of the membrane‐binding domain of penicillin‐binding protein 5 of Escherichia coli
Yang et al. Identification of the products and nucleotide sequences of two regulatory genes involved in the exogenous induction of phosphoglycerate transport in Salmonella typhimurium
PL181695B1 (pl) Sposób ekspresji bialka blony zewnetrznej P2 Haemophilus influenzae typu b (Hib-P2) w komórkach E.coli, szczepionka przeciwko Haemophilus influenzae typu boraz wektory ekspresyjne PL
Bishai et al. Cloning and expression in Escherichia coli of three fragments of diphtheria toxin truncated within fragment B
ES2528330T3 (es) Compartimentación de polipéptidos recombinantes en células anfitrionas
Viaplana et al. Polylinker‐encoded peptides can confer toxicity to recombinant proteins produced in Escherichia coli
Taira et al. Amino-terminal sequence analysis of four plasmid-encoded virulence-associated proteins of Salmonella typhimurium
EP1233024A3 (en) 25466, a human transporter family member and uses therefor
ATE126701T1 (de) Äusseres membranprotein p1 und peptide von haemophilus influenzae typ b.
US20090220517A1 (en) Method for producing epitomers and their uses on carrier microorganisms
DE69032453T2 (de) Expressionsvektoren und verfahren zur herstellung intrazellularer proteine
Houard et al. Cloning, expression and purification of recombinant cotton rat interferon-gamma
ATE254178T1 (de) Expression heterologer proteine in abgeschwächten bakterien mittels des htra-promotors
CN111808202A (zh) 产气荚膜梭菌基因工程亚单位疫苗、其制备方法及应用
AU2002352068A1 (en) 2150, a human protein kinase family member and uses therefor
KORNACKI DNA REPLICATION CONTROL OF BROAD HOST RANGE PLASMID RK2 (IN VITRO REPLICATION, PLASMID-ENCODED PROTEINS, AUTOREGULATION, DNA/MEMBRANE COMPLEX)

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ RU